The human monoclonal antibody known as tralokinumab-ldrm was tested and approved as a safe, effective treatment for pediatric patients with atopic dermatitis aged 12 to 17 years old. Originally ...
Please provide your email address to receive an email when new articles are posted on . The study included adolescents aged 12 to 17 years and adults. Comorbidities included asthma, food allergy, hay ...
LEO Pharma A/S, a global leader in medical dermatology, today announced the positive results from a 16-week interim analysis of the Phase 3b ADHAND trial evaluating tralokinumab for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results